

REMARKS

The Examiner has required an election under 35 U.S.C. § 121 of one of the following inventions:

- I. Claims 1-5, drawn to methods of detecting a mutation in the FGF20 gene, classified in class 435, subclass 6.
- II. Claims 6-8, drawn to methods for detecting a mutation in the FGF20 protein, classified in class 435, subclass 7.2.
- III. Claims 9-14, drawn to methods for detecting the level of FGF20 protein as indicative of hypophosphatemic condition, classified in class 435, subclass 7.1.
- IV. Claim 14, drawn to methods for detecting the level of FGF20 mRNA as indicative of a hypophosphatemic condition, classified in class 435, subclass 6.
- V. Claims 15 and 16, drawn to methods of treating a hypophosphatemic condition by administering a compound that reduces the level of FGF20 mRNA, classified in class 514, subclass 44.
- VI. Claims 15 and 16, drawn to methods of treating a hypophosphatemic condition by administering a compound that reduces the level of FGF20 polypeptides, classified in class 424, subclass 131.1.
- VII. Claim 15 and 16, drawn to methods of treating a hypophosphatemic condition by administering a compound that inhibits the activity of FGF20 polypeptides, classified in class 514, subclass 1.
- VIII. Claims 17 and 18, drawn to methods of treating a hyperphosphatemic condition by administering FGF20 nucleic acids.
- IX. Claims 19, 20 and 25, drawn to methods of treating a hyperphosphatemic condition by administering FGF20 polypeptides, classified in class 514, subclass 1.
- X. Claims 21, 22 and 25, drawn to methods of treating a hyperphosphatemic condition by administering a compound that increase the level of FGF20 polypeptides, classified in class 514, subclass 1.

XI. Claims 23 and 24, drawn to methods of treating a hyperphosphatemic condition comprising administering a population of cells comprising FGF20 nucleic acids, classified in class 424, subclass 93.1.

The Examiner contends that the inventions are distinct each from the other.

The Examiner has required further election of one inhibitor, should Applicant elect inventions V, VI or VII.

In response, Applicants hereby elect the invention of group IX, Claims 19, 20 and 25, drawn to methods of treating a hyperphosphatemic condition by administering FGF20 polypeptides, classified in class 514, subclass 1.

CONCLUSION

Applicant respectfully requests that the present remarks be made of record in the instant application. Applicant submits that this application is in condition for allowance and such action is respectfully requested. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Date: February 15, 2006


Ivor R. Elrifi

39,529
(Reg. No.)

Attorney for Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Tel: (617) 542-6000

Fax: (617) 542-2241

Customer No.: 55111